This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ISOLDE evaluated whether MABA was no less effective than EIBI when children with autism spectrum disorder were assessed using the Vineland Adaptive Behavior Scale (VABS-3).
| Feature | ISOLDE |
|---|---|
| NCT ID | NCT04078061 |
| Status | COMPLETED |
| Condition | Autism Spectrum Disorder |
| Sponsor | University of Rochester |
| Allocation | RANDOMIZED |
| Design model | PARALLEL |
| Masking | SINGLE |
| Interventions | MABA (behavioral); EIBI (behavioral) |
2. Clinical Question
Population
Children with autism spectrum disorder.
Intervention
MABA, a behavioral intervention.
Comparator
EIBI, a behavioral intervention.
Primary question
Whether MABA is no less effective than EIBI when assessed using VABS-3.
3. Trial Design
Participants were assigned using a randomized design.
Parallel-group treatment comparison with two arms.
The registry reports a single-masked design.
The primary purpose was treatment evaluation.
MABA
Behavioral intervention evaluated as one randomized arm.
EIBI
Behavioral intervention serving as comparator arm.
4. Endpoints
| Endpoint | Time frame | Description |
|---|---|---|
| Change in Vineland Adaptive Behavior Scale (VABS-3) | Baseline, Week4, Week 12, Week24, Week48, Week 90, Age 5 | Adaptive skills measured across Communication, Daily Living Skills, and Socialization domains. |
5. Planned Analysis
The ClinicalTrials.gov record reports the primary endpoint but does not report posted statistical analyses or trial results. The primary question is framed as a non-inferiority hypothesis: MABA would be no less effective than EIBI when children are assessed using VABS-3.
For a continuous outcome such as change in VABS-3 score, statistical analysis would typically compare the estimated difference in change between randomized groups and evaluate whether the uncertainty around that difference is compatible with the prespecified non-inferiority criterion. The registry does not report the statistical model, non-inferiority margin, confidence interval, or p-value used for this analysis.
6. Statistical Methodology
Randomized comparison
Randomization creates the basis for comparing outcomes between intervention groups because treatment assignment is determined independently of participant characteristics. In a randomized parallel design, the comparison of outcome changes is intended to estimate differences attributable to the assigned interventions.
Repeated outcome assessment
The VABS-3 endpoint was measured across multiple time points, including baseline and follow-up assessments. Longitudinal outcomes are commonly analyzed using methods that account for repeated observations from the same participant, although the registry does not report the specific statistical approach used.
Non-inferiority framework
Non-inferiority trials ask whether an intervention is not meaningfully worse than an established comparator by more than a prespecified amount. Interpretation depends on the chosen margin, the confidence interval around the treatment difference, and preservation of the comparator's expected effect.
7. Statistical Methods Explained
Why was VABS-3 selected as the primary endpoint?
The registry states that VABS-3 was selected because it measures adaptive skills relevant to everyday settings and includes Communication, Daily Living Skills, and Socialization domains.
What does “no less effective” mean statistically?
In a non-inferiority design, the question is not whether two treatments are identical. The question is whether the new approach remains within an acceptable difference from the comparator.
Why are repeated measurements useful?
Measurements collected over time allow investigators to examine change in adaptive behavior rather than relying only on a single endpoint assessment.
Why does the confidence interval matter?
The confidence interval describes uncertainty around an estimated treatment difference. A narrow interval provides more precision than a wide interval.
8. Limitations
- No posted statistical analyses: ClinicalTrials.gov does not report statistical estimates, confidence intervals, or p-values for the primary endpoint.
- Non-inferiority interpretation: The registry does not report the non-inferiority margin or final analysis method.
- Missing methodology details: The registry does not report model specification, missing-data handling, or analysis population definitions.
- Generalizability: Applicability depends on the enrolled population and study setting.
9. Why This Trial Matters Statistically
| Concept | How it appears in ISOLDE |
|---|---|
| Randomization | Randomized parallel-group comparison. |
| Non-inferiority testing | Primary hypothesis that MABA would be no less effective than EIBI. |
| Longitudinal outcomes | VABS-3 measured from baseline through multiple follow-up points. |
| Patient-reported/developmental assessment | Adaptive behavior measured using VABS-3 domains. |